Ata3219
Lupus Nephritis, Systemic Lupus Erythematosus
Phase I
Withdrawn
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
May 21, 2024
―
Ata3219
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Phase I
Terminated
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Feb 05, 2024
―
Pembrolizumab, Tabelecleucel, Tab-Cel
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Epstein-Barr Viraemia, Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma (Ebv+ Npc)
Phase I/II
Terminated
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Nov 29, 2018
―
Tab-Cel, Ebvallo, Tabelecleucel
Lymphoproliferative Disorders, Solid Organ Transplant Complications, Stem Cell Transplant Complications, Epstein-Barr Virus+ Associated Post-Transplant Lymphoproliferative Disease (Ebv+ Ptld), Allogeneic Hematopoietic Cell Transplant
Phase III
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Dec 29, 2017
―
Tabelecleucel, Tab-Cel, Ebv-Specific T Cells
Ebv-Induced Lymphomas, Ebv-Associated Malignancies, Transplant Patients With Ebv Viremia At High Risk For Developing A Recurrent Ebv Lymphoma
Phase II
Completed
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Dec 21, 2011
―
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Ebv-Induced Lymphomas, Ebv-Associated Malignancies, Transplant Patients With Ebv Viremia At High Risk Of Developing A Recurrent Ebv Lymphoma
Phase I/II
Completed
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Nov 01, 1999
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Atara Biotherapeutics (ATRA) have in its pipeline
ATRA is currently developing the following drugs: Ata3219, Ata3219, Pembrolizumab, Tabelecleucel, Tab-Cel. These drug candidates are in various stages of clinical development as the company works toward FDA approval.